A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-linked chronic granulomatous disease
This research is looking into a new way to treat X-linked Chronic Granulomatous Disease, or X-CGD. X-CGD is a condition where the body's immune system struggles to fight certain infections. The study uses a special type of gene therapy. Doctors take some of the patient's own blood cells, make a change in them in the lab, and then put them back into the patient. The aim is for these changed cells to help the immune system work properly again. Researchers want to find out if this treatment is safe and if it can help patients fight off infections better. They are also checking if the body continues to make these helpful cells over time. This is an early stage study, meaning it's one of the first times this treatment is being tried in people.
במבט חטוף
על מה המחקר הזה?
This study is a clinical trial exploring a new gene therapy for a serious inherited immune condition called X-linked Chronic Granulomatous Disease (X-CGD). People with X-CGD have a faulty gene that stops their immune cells from killing certain germs, leading to severe and recurrent infections and sometimes chronic inflammation. Current treatments help manage the symptoms, but researchers are always looking for better solutions.
The new treatment involves taking some special blood cells rich in stem cells, called CD34+ cells, from the patient's own body. These cells are then sent to a lab where scientists introduce a working copy of the faulty gene into them using a specially designed virus, called a lentiviral vector. This virus acts like a delivery truck, carrying the healthy gene into the cells. Once the cells have the working gene, they are given back to the patient. The hope is that these corrected cells will then produce healthy immune cells, helping the body to fight off infections more effectively.
The main goals of this study are to carefully check the safety of this new treatment and to see if it helps improve the patient's immune system. Researchers will be looking for any side effects and will also measure if the patient's immune cells start working properly again at least a year after the treatment. They will also observe if the treatment improves overall health, helps clear existing infections, and how long the corrected cells last in the body.
נקודות עיקריות
- This is an early-stage gene therapy study for X-linked Chronic Granulomatous Disease (X-CGD).
- It uses your own modified cells to try and improve your immune system.
- The main goals are to check the treatment's safety and see if it helps fight infections.
- Only men aged 18 and over with X-CGD can take part.
- Participation involves regular check-ups and a long-term follow-up.
- Potential benefits and risks will be discussed in detail by the study team.
מי עשוי להיות זכאי?
This study is looking for volunteers who have been diagnosed with X-linked Chronic Granulomatous Disease (X-CGD). Importantly, only men are able to participate in this specific study, as X-CGD primarily affects males.
Participants must be at least 18 years old. There is no upper age limit, meaning older adults are also welcome to be considered for the study. Doctors will carefully review each potential participant's medical history to make sure the study is a good fit and safe for them.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Do you have a diagnosis of X-linked Chronic Granulomatous Disease (X-CGD)?
- האם אתה זכר?
- האם אתה בן 18 או יותר?
- Are you able to commit to long-term follow-up and regular hospital visits?
מה כרוך בהשתתפות?
Taking part in this study would involve a series of steps. First, doctors would collect some of your blood cells, which will be specially prepared in a lab. There would be a period where you might receive some conditioning medicine to prepare your body for the modified cells. After receiving the modified cells, there will be regular hospital visits and assessments to monitor your health, check for any side effects, and see how well the treatment is working. This will include blood tests and other examinations. The study involves long-term follow-up to track your health and the effects of the treatment over time, potentially for many years. The exact number of visits and the full duration of follow-up will be explained in detail by the study team.
סיכונים ותועלות פוטנציאליים
מיקומים (1)
- —לא מאומתצרפת
שאלות נפוצות
What is X-linked Chronic Granulomatous Disease (X-CGD)?
It's a rare inherited condition where your immune system has trouble fighting off certain bacteria and fungi, leading to severe infections.
What is a 'gene therapy'?
Gene therapy aims to fix a problem by introducing a healthy copy of a gene into your cells to help them work properly.
Will I get 'cured' by this treatment?
This is an early stage study, so the main goals are to check safety and see if the treatment helps improve immune function. We cannot promise a cure.
What kind of commitment is involved?
You'd need to commit to regular hospital visits, tests, and long-term follow-up to monitor your health and the treatment effects.
Can women participate in this study?
No, this particular study is only for men who have been diagnosed with X-CGD.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.